Trioday

Indications for taking of the remedy Trioday.

Treatment of HIV-1 infection in combination antiretroviral therapy in adults.

Contraindications of Trioday.

Tenofovir is contraindicated in patients with hypersensitivity to any component of the remedy.

You should take Trioday with caution.

Renal failure with creatinine clearance less than 50 ml / min, including patients on hemodialysis. When creatinine clearance is less than 30 ml / min, use of the remedy should be avoided; in the event that other treatment is not available, the kidney function should be carefully monitored and the interval between administration of the remedy should be adjusted.

Pregnancy and lactation period during taking of Trioday.

When you decided to take the remedy in pregnancy, it is necessary to correlate the expected therapeutic effect for the mother with the possible risk of using the remedy for the fetus. In connection with the revealed changes in bone tissue on the background of taking the remedy, and limited experience of use, it is recommended to use the remedy with caution during pregnancy. Women of childbearing age during treatment should use reliable methods of contraception. Nursing mothers: HIV-infected women should be instructed to exclude breastfeeding.

Dosing and Administration of Trioday.

The remedy is taken inside, regardless of food intake. The recommended dose for the treatment of HIV-1 infection is 300 mg once a day. The recommended dosing regimen Trioday in renal failure: Creatinine clearance 30-49 ml / min: 300 mg every 48 hours. Creatinine clearance 10-29 ml / min: 300 mg every 72-96 h. Hemodialysis: 300 mg every 7 days after the end of the session dialysis. Recommendations on the dosage regimen in patients with creatinine clearance less than 10 ml / min (without hemodialysis) are absent.

Combined retro viral therapy was associated with metabolic disorders such as hypertriglyceridemia, hypercholesterolemia, insulin resistance, hyperglycemia and hyperlactatemia; redistribution of subcutaneous tissue (lipodystrophy).
Osteonecrosis cases have been reported, especially in patients with risk factors or with long-term combined antiviral therapy. The frequency is unknown.